Is GLAUKOS Corp (GKOS) Halal?

NYSE Healthcare United States $6.0B
✓ HALAL
Confidence: 95/100
GLAUKOS Corp (GKOS) is Halal under all 5 major Shariah screening standards. With a debt ratio of just 1.7% against the AAOIFI threshold of 30%, GLAUKOS Corp comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Medical Devices), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.7%
/ 30%
4.5%
/ 30%
1.7%
/ 30%
2.11%
/ 5%
✓ HALAL
DJIM 1.7%
/ 33%
4.5%
/ 33%
1.7%
/ 33%
2.11%
/ 5%
✓ HALAL
MSCI 11.6%
/ 33%
31.2%
/ 33%
12.2%
/ 33%
2.11%
/ 5%
✓ HALAL
S&P 1.7%
/ 33%
4.5%
/ 33%
1.7%
/ 33%
2.11%
/ 5%
✓ HALAL
FTSE 11.6%
/ 33%
31.2%
/ 33%
12.2%
/ 50%
2.11%
/ 5%
✓ HALAL

Financial Highlights

EPS
$-3.28
P/B Ratio
9.0
EV/EBITDA
-119.6
EV: $5.8B
Revenue
$507M
Growth: 35.7%
Beta
0.7
Low volatility
Current Ratio
4.7

Profitability

Gross Margin 78.0%
Operating Margin -18.9%
Net Margin -37.0%
Return on Equity (ROE) -26.4%
Return on Assets (ROA) -5.8%

Cash Flow & Balance Sheet

Operating Cash Flow-$15M
Free Cash Flow-$39M
Total Debt$104M
Debt-to-Equity16.2
Current Ratio4.7
Total Assets$893M

Price & Trading

Last Close$107.75
50-Day MA$113.00
200-Day MA$99.71
Avg Volume760K
Beta0.7
52-Week Range
$73.16
$130.23

About GLAUKOS Corp (GKOS)

CEO
Mr. Thomas William Burns
Employees
1,094
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NYSE
Market Cap
$6.0B
Currency
USD

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Purification Calculator

As a halal stock with 2.11% impermissible income, you need to purify your dividends.

Enter your dividends to calculate purification amount

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is GLAUKOS Corp (GKOS) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), GLAUKOS Corp is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is GLAUKOS Corp's debt ratio?

GLAUKOS Corp's debt ratio is 1.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.6%.

Does GLAUKOS Corp require dividend purification?

Yes, GLAUKOS Corp has an impermissible income ratio of 2.11%, which means 2.11% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.

What are GLAUKOS Corp's key financial metrics?

GLAUKOS Corp has a market capitalization of $6.0B, and revenue of $507M. The company maintains a gross margin of 78.0% and a net margin of -37.0%. Return on equity stands at -26.4%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.